S91
Brachytherapy - Gynaecology
ESTRO 2026
(25.8%), stage III (15.4%), and stage IV (29.8%), with squamous cell carcinoma being the predominant histology (85.7%). The mean EBRT dose was 48.17 ± 9.25, while the mean BT dose was 22.57 ± 3.73. 21 patients (11.5%) had 1-2 fractions while 161(88.5%) had 3-4 fractions. The overall survival within the study period was 88.5%. Kaplan Meier showed a mean survival time of 24.7 ± 2.09 months and a median survival time of 21.5 ± 3.16 months. Conclusion: The study shows an increase in the utilisation of brachytherapy and good overall survival. However, the overall utilisation remains low as international guidelines require that the treatment for all locally advanced cervical cancer is curative external beam radiotherapy with concurrent chemotherapy, followed by intracavitary brachytherapy. This study, therefore, highlights the need to address these barriers for improved utilisation of brachytherapy. Keywords: Brachytherapy, Utilization, Survival References: 1. Kambhampati A, Meghani K, Ndlovu N, Monare B, Mutimuri M, Bazzett-Matabele L, et al. A Multi- Institutional Study of Barriers to Cervical Cancer Care in Sub-Saharan Africa. Adv Radiat Oncol [Internet]. 2023 Sep 1. Available from: https://www.advancesradonc.org/article/S2452- 1094(23)00086-6/fulltext2.Adegboyega B, Alabi A, Bashir M, Njoku E. EV372/#1207 Clinical outcomes of 3D gyneacological cancer brachytherapy in NSIA – LUTH cancer centre. Int J Gynecol Cancer [Internet]. 2024 Oct 1 [cited 2024 Dec 16];34(Suppl 3). Available from: https://ijgc.bmj.com/content/34/Suppl_3/A277.3
Made with FlippingBook - Share PDF online